Guardant Health, Inc.

Guardant Health, Inc.

132.80
EUR
+1.08
(+0.82%)
-3.25EPS
21.25BMarket Cap
Feb 25Next Earn

Total Valuation

EUR

As of September 30, 2026, Guardant Health, Inc. carries a market capitalization of 21.25B, placing it among publicly traded companies globally. Its enterprise value stands at 21.83B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap21.25B
Enterprise Value21.83B

Important Dates

Guardant Health, Inc.'s next confirmed earnings release is scheduled for February 25, 2027.

Earnings Date2/25/2027

Share Statistics

As of September 30, 2026, Guardant Health, Inc. has 134.72M shares outstanding.

Shares Outstanding134.72M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 18.42, and the price-to-book ratio stands at -87.29.

PS Ratio18.42
PB Ratio-87.29
P/TBV Ratio-63.69
P/FCF Ratio-101.49
P/OCF Ratio-135.82

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 19.35 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 21.83B versus a market cap of 21.25B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales19.35

Financial Position

As of September 30, 2026, Guardant Health, Inc. maintains a current ratio of 3.60, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -613.06, indicating conservative leverage, while an interest coverage ratio of -89.08 demonstrates limited ability to service its debt obligations.

Current Ratio3.60
Quick Ratio3.25
Debt / Equity-613.06
Debt / EBITDA-3.64
Interest Coverage-89.08

Financial Efficiency

EUR

These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -30.68, reflecting losses generated across the asset base. The company generates approximately 450,263.11 in revenue per employee across its workforce of 2,506.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.84 indicates how many times Guardant Health, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-30.68
Revenue Per Employee450,263.11
Employee Count2,506.00
Inventory Turnover4.84

Taxes

EUR

Over the twelve months ended September 30, 2026, Guardant Health, Inc. recorded an income tax benefit of -729,662.10 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -428.71M and -427.98M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-729,662.10

Stock Price Statistics

EUR

As of the close on November 17, 2026, Guardant Health, Inc.'s stock has gained approximately 59.85% over the past 52 weeks. The 50-day moving average sits at 148.79, while the 200-day moving average is 116.74.

52-Week Price Change59.85%
50-Day Moving Average148.79
200-Day Moving Average116.74

Income Statement

EUR

Over the twelve months ended September 30, 2026, Guardant Health, Inc. generated 1.13B in revenue and converted that into -427.98M in net income, yielding earnings per share of -3.25. EBITDA reached -410.10M, while operating income came in at -444.71M.

Revenue1.13B
Gross Profit735.58M
Operating Income-444.71M
Pretax Income-428.71M
Net Income-427.98M
EBITDA-410.10M
EBIT-444.71M
Earnings Per Share (EPS)-3.25

Balance Sheet

EUR

As of September 30, 2026, Guardant Health, Inc. holds 905.99M in cash and equivalents against 1.49B in total debt, resulting in a net debt position of 419.59M. Total book value stands at -243.43M, with working capital of 856.04M providing operational flexibility.

Cash & Cash Equivalents905.99M
Total Debt1.49B
Net Debt419.59M
Equity (Book Value)-243.43M
Book Value Per Share-1.81
Working Capital856.04M

Cash Flow

EUR

Guardant Health, Inc. produced -153.06M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -51.76M in capital expenditures, free cash flow totaled -204.82M - equivalent to -1.55 per share.

Operating Cash Flow-153.06M
Capital Expenditures-51.76M
Free Cash Flow-204.82M
FCF Per Share-1.55

Margins

Over the twelve months ended September 30, 2026, Guardant Health, Inc. posted a gross margin of 65.19, reflecting its pricing power and cost economics. The operating margin of -39.41 and net profit margin of -37.93 provide insight into operational efficiency.

Gross Margin65.19
Operating Margin-39.41
Pretax Margin-37.99
Profit Margin-37.93
EBITDA Margin-36.34

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -0.99: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -3.11, meaning Guardant Health, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-3.11
FCF Yield-0.99

Scores

As of September 30, 2026, Guardant Health, Inc. has an Altman Z-Score of 4.49, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.49